
ARAY — Accuray Incorporated
NASDAQ · Healthcare · Medical Devices
$0.26
+$0.00 (+0.20%)
Accuray Incorporated (ARAY) is a medical devices company listed on NASDAQ. It is led by Suzanne Winter M.B.A., based in 1240 Deming Way, Madison, WI, United States, 53717-1954, with about 987 employees. Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Latest reported ARAY revenue for 2025-09-30 was $93.9M. Net income was -$21.7M. Revenue was down 79.5% from 2025-06-30 to 2025-09-30. ARAY currently screens at market cap $140.1M.
Use this ARAY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARAY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARAY SEC filings page. Lician reads the product cache first so this HTML stays unique to Accuray Incorporated even when a live quote feed is slow.
About Accuray Incorporated
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
ARAY Key Statistics
Market Cap
$140.10M
Volume
196,670
Previous Close
$0.27
Day Range
$0.27 – $0.29
EPS
-$0.02
Revenue
$458.50M
Net Income
-$1.59M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+2.7%
Profit Margin
-0.3%
Employees
987
ARAY Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $458.50M | $446.55M | $447.61M | $429.91M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.59M | -$15.54M | -$9.28M | -$5.35M |
| EPS (Diluted) | -$0.02 | -$0.16 | -$0.10 | -$0.06 |
Total Assets
$470.24M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$57.42M
Operating Cash Flow
$2.86M
Free Cash Flow
$0.00
Accuray Incorporated Company Information
- President, CEO & Director
- Suzanne Winter M.B.A.
- Headquarters
- 1240 Deming Way, Madison, WI, United States, 53717-1954
- Website
- www.accuray.com
- Phone
- 608 824 2800
- IPO / Founded
- 2007-02-08
- Sector
- Healthcare
- Industry
- Medical Devices